Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG6ZU4)

Drug Name

Lanreotide acetate Drug Info

Synonyms

Lanreotide; Angiopeptin acetate; Somatuline; Somatulin; 127984-74-1; DC 13-116; Autogel; 108736-35-2; BIM 23014; Bim-23014; Lanreotide [INN:BAN]; Lanreotidum [INN-Latin]; Lanreotida [INN-Spanish]; Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2; 10-(4-Aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide; Somatuline lp (TN); Lanreotide Autogel

Indication

Disease Entry	ICD 11	Status	REF
Acromegaly	5A60.0	Approved	[1]

Cross-matching ID

PubChem CID: 71349
CAS Number: CAS 108736-35-2
TTD Drug ID: DMG6ZU4
ACDINA Drug ID: D01195

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Somatostatin receptor type 2 (SSTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pasireotide	DMHM7JS	Cushing disease	5A70	Approved	[2]
Octreotide	DMHIDCJ	Acromegaly	5A60.0	Approved	[3]
Ga-68-DOTATOC	DMZ0P95	Diagnostic imaging	N.A.	Approved	[4]
Copper dotatate Cu-64	DM26KR1	Diagnostic imaging	N.A.	Approved	[5]
ODT-8	DMBWO5T	N. A.	N. A.	Phase 3	[6]
Paltusotine	DM97IN2	Acromegaly	5A60.0	Phase 3	[7]
TBR-760	DMM5BVG	Pituitary adenoma	2F37.0	Phase 2	[8]
Re-188-P-2045	DM614BA	Lung cancer	2C25.0	Phase 1/2	[9]
PEN-221	DMMAUOK	Neuroendocrine cancer	2B72.1	Phase 1/2	[10]
FR-121196	DMNRUGA	Alzheimer disease	8A20	Terminated	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Somatostatin receptor type 2 (SSTR2)	TTZ6T9E	SSR2_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
3	Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
7	Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary. 2022 Apr;25(2):328-339.
8	TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.
9	The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5.
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11	Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34.